Opinion|Videos|September 24, 2024
Role of MRAs in HFmrEF and HFpEF
Author(s)Javed Butler, MD, MPH, MBA
Javed Butler, MD, MPH, MBA, discusses the current mineralocorticoid receptor antagonists (MRAs) used for heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF, emphasizing the role of nonsteroidal MRAs such as finerenone, and explore how the FINEARTS-HF results could translate into real-world benefits and inform the clinical pathway for these patients.
Advertisement
Video content above is prompted by the following:
- Which mineralocorticoid receptor antagonists (MRAs; ie, steroidal, nonsteroidal) are currently indicated or used for treating heart failure with midrange ejection fraction (HFmrEF) and HF failure with preserved EF (HFpEF), and what role does a nonsteroidal MRA such as finerenone have to offer in this treatment landscape based on the results of FINEARTS-HF?
- How might these results translate into real-world benefit, and where do you see their place in the clinical pathway for patients with HFmrEF or HFpEF?
Advertisement
Related to this article
Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.
In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.
From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.
The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.
New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
A new meta-analysis finds pulmonary rehabilitation and other nonpharmacological interventions ease lung cancer cough, dyspnea, and improve QOL.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5